Adalimumab maintenance therapy for Crohn’s disease with intolerance or lost response to infliximab: an open-label study
Version of Record online: 16 JAN 2007
Alimentary Pharmacology & Therapeutics
Volume 25, Issue 6, pages 675–680, March 2007
How to Cite
PEYRIN-BIROULET, L., LACLOTTE, C. and BIGARD, M.-A. (2007), Adalimumab maintenance therapy for Crohn’s disease with intolerance or lost response to infliximab: an open-label study. Alimentary Pharmacology & Therapeutics, 25: 675–680. doi: 10.1111/j.1365-2036.2007.03254.x
- Issue online: 22 JAN 2007
- Version of Record online: 16 JAN 2007
- Publication data Submitted 13 November 2006 First decision 15 November 2006 Submitted 8 January 2007 Accepted 9 January 2007
- 2A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997; 15: 1029–35., , , et al.
- 9Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC-II trial. Gut (in press)., , , et al.
- 12Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn’s disease: results from a 26-week, placebo-controlled phase III study (PRECISE 1). Gastroenterology 2006; 130(Suppl. 2): A107., , , et al.
- 13Certolizumab pegol, a humanised anti-TNF pegylated Fab′ fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn’s disease: a phase III study (PRECISE). Gut 2005; 54(Suppl.): A82., , , et al.
- 14An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am J Gastroenterol 2004; 99: 1984–9., , , et al.Direct Link:
- 16Adalimumab rapidly induces clinical response and remission in patients with moderate to severe Crohn’s disease who had secondary failure to infliximab therapy: results of the GAIN study. Gut 2006; 55(Suppl.): A21., , , , , .
- 17Safety and efficacy of adalimumab (D2E7) in Crohn’s disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005; 100: 75–9., , , et al.Direct Link: